Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DSS BioHealth Security
Houston, Texas, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
DSS BioHealth Security serves as a holding entity for biohealth and biomedical assets, most notably controlling Impact Biomedical, which is developing products for neurological, oncological, and immune-related conditions; Impact Biomedical reports promising preclinical results with technologies such as Linebacker, Equivir, and 3F Functional Fragrance, but there are no marketed or late-stage clinical assets under DBH's direct ownership.
- Therapeutic areas
- ImmunologyInfectious DiseasesNeurologyOtherOncology
- Modalities
- Small moleculeFragrance-based bioactive
- Industry
- Investors
02
Partnerships
Impact Biomedical has licensing agreements with ProPhase Labs for Equivir and Linebacker
Beyond the preview
Go deeper on DSS BioHealth Security.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DSS BioHealth Security.